

03 December 2025

Admissions and prescribed medications for COPD

Q1. Within your Trust, how many patients in total were admitted as inpatients between July – October 2025 with a primary cause of admission being a chronic obstructive pulmonary disease (COPD) exacerbation (ICD-10: J44.1)?

Q2. Of the patients admitted with a primary COPD exacerbation (ICD-10: J44.1) identified in Q1, how many were already prescribed a closed triple therapy* at the point of admission?

***Closed triple therapy = Trelegy, Trixeo, or Trimbow (any formulation)**

****“Already prescribed” means the therapy was documented as active on admission, either from hospital records or patient-reported history.**

**Q3. How many patients in total were prescribed Trixeo for COPD (ICD-10: J44.1) between July – October 2025?
How many of these were new to Trixeo*?**

***New to Trixeo = Patient not prescribed Trixeo in your hospital (inpatient or outpatient) in the past 12 months (Nov 2024 – Oct 2025), and not currently prescribed Trixeo—whether prescribed in hospital or community settings—at the point of admission.**

Q4. How many patients in total were prescribed Trimbow MDI (for COPD [ICD-10: J44.1]) between July – October 2025?

- **How many of these were new to Trimbow MDI*?**
- **Of the new Trimbow MDI patients*, what was the split between:**
- **Trimbow MDI 87/5/9**
- **Trimbow MDI 172/5/9**

***New to Trimbow MDI = Patient not prescribed Trimbow MDI in your hospital (inpatient or outpatient) in the past 12 months (Nov 2024 – Oct 2025), and not currently prescribed Trimbow MDI—whether prescribed in hospital or community settings—at the point of admission.**

**Q5. How many patients in total were prescribed Trelegy for COPD (ICD-10: J44.1) between July – October 2025?
How many of these were new to Trelegy*?**

03 December 2025

***New to Trelegy = Patient not prescribed Trelegy in your hospital (inpatient or outpatient) in the past 12 months (Nov 2024 – Oct 2025), and not currently prescribed Trelegy—whether prescribed in hospital or community settings—at the point of admission.**

**Q6. How many patients in total were prescribed Trimbow DPI (for COPD [ICD-10: J44.1]) between July – October 2025?
 How many of these were new to Trimbow DPI*?**

***New to Trimbow DPI = Patient not prescribed Trimbow DPI in your hospital (inpatient or outpatient) in the past 12 months (Nov 2024 – Oct 2025), and not currently prescribed Trimbow DPI—whether prescribed in hospital or community settings—at the point of admission.**

To extract this information would take significantly more than 18 hours in total to provide in full, however we have some information to share from transactions related to Triple Inhalers for all dispensaries in BHSCT.

Transaction can either be a delivery or a supply from pharmacy so not fully representative of number of inhalers we have supplied to patients but will give a rough estimate of usage as we will order in to replace what has been used.

27 May – 26 Nov 2025	Number of Medication Inventory Transactions
	1,780,522
Budesonide, formoterol fumarate and glycopyrronium	885
Fluticasone furoate and umeclidinium and vilanterol	1,308
Beclometasone extrafine particle and formoterol and glycopyrronium	1,792